Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Darioli

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Schweizerische Medizinische Wochenschrift|December 16, 1989
[Hyper-HDL-cholesterolemia: prevalence and clinical aspects]J F Luthi, R Darioli, P Kuhn, et al.
Schweizerische Medizinische Wochenschrift|December 31, 1988
[Comparison of fructosamine and Hba1c for the evaluation of metabolic control of diabetic patients]H Veillon, P Bovet, P A Buchard, et al.
Schweizerische Medizinische Wochenschrift|November 13, 1993
[Association between lipoprotein(a) and coronary disease]P Bovet, B Burnand, L Kappenberger, et al.
Revue Medicale Suisse|May 8, 2008
[Value of nuclear medicine in preventive cardiology: the metabolic syndrome example]J O Prior, G Allenbach, J-C Masson, et al.
Schweizerische Medizinische Wochenschrift|December 3, 1988
[Screening for and treatment of risk factors of cardiovascular diseases: need for a strategy?]P Bovet, R Darioli, B Janin, et al.
Schweizerische Medizinische Wochenschrift|June 20, 1987
[Comparative study of the treatment of simple urinary infection with a single dose of norfloxacin versus cotrimoxazole]P de Vevey, R Darioli, J Bille, et al.
Schweizerische Medizinische Wochenschrift|March 15, 1986
[The role of colorimetry strips in routine urine analysis in ambulatory practice]C Bonard, R Darioli, A Petrillo, et al.
Sozial- Und Praventivmedizin|January 1, 1991
The Seychelles cardiovascular diseases survey 1989P Bovet, D Rosalie, C Shamlaye, et al.
Revue Medicale Suisse|April 7, 2006
[Evolution of cardiac risk factors management among patients aged 65 years and older with coronary artery disease]A Hobi, S Roy, C Vuille, et al.
Praxis|May 24, 2000
[Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study]T D Szucs, O Bertel, R Darioli, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Schweizerische Medizinische Wochenschrift|December 16, 1989
[Hyper-HDL-cholesterolemia: prevalence and clinical aspects]J F Luthi, R Darioli, P Kuhn, et al.
Schweizerische Medizinische Wochenschrift|December 31, 1988
[Comparison of fructosamine and Hba1c for the evaluation of metabolic control of diabetic patients]H Veillon, P Bovet, P A Buchard, et al.
Schweizerische Medizinische Wochenschrift|November 13, 1993
[Association between lipoprotein(a) and coronary disease]P Bovet, B Burnand, L Kappenberger, et al.
Revue Medicale Suisse|May 8, 2008
[Value of nuclear medicine in preventive cardiology: the metabolic syndrome example]J O Prior, G Allenbach, J-C Masson, et al.
Schweizerische Medizinische Wochenschrift|December 3, 1988
[Screening for and treatment of risk factors of cardiovascular diseases: need for a strategy?]P Bovet, R Darioli, B Janin, et al.
Schweizerische Medizinische Wochenschrift|June 20, 1987
[Comparative study of the treatment of simple urinary infection with a single dose of norfloxacin versus cotrimoxazole]P de Vevey, R Darioli, J Bille, et al.
Schweizerische Medizinische Wochenschrift|March 15, 1986
[The role of colorimetry strips in routine urine analysis in ambulatory practice]C Bonard, R Darioli, A Petrillo, et al.
Sozial- Und Praventivmedizin|January 1, 1991
The Seychelles cardiovascular diseases survey 1989P Bovet, D Rosalie, C Shamlaye, et al.
Revue Medicale Suisse|April 7, 2006
[Evolution of cardiac risk factors management among patients aged 65 years and older with coronary artery disease]A Hobi, S Roy, C Vuille, et al.
Praxis|May 24, 2000
[Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study]T D Szucs, O Bertel, R Darioli, et al.
Pageof 8